Total Payments
$350.13
2023 Payments
$36.74
Companies
8
Transactions
20
Medicare Patients
974
Medicare Billing
$209,476
Payment Breakdown by Category
Food & Beverage$336.20 (96.0%)
Education$13.93 (4.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $336.20 | 19 | 96.0% |
| Education | $13.93 | 1 | 4.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $131.97 | 6 | $0 (2019) |
| Pharmacyclics LLC, An AbbVie Company | $64.42 | 4 | $0 (2023) |
| Merck Sharp & Dohme LLC | $45.70 | 4 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $40.38 | 2 | $0 (2018) |
| Celgene Corporation | $19.60 | 1 | $0 (2022) |
| Janssen Biotech, Inc. | $19.27 | 1 | $0 (2022) |
| PFIZER INC. | $14.86 | 1 | $0 (2018) |
| Acrotech Biopharma LLC | $13.93 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $36.74 | 2 | Pharmacyclics LLC, An AbbVie Company ($36.74) |
| 2022 | $98.50 | 7 | Merck Sharp & Dohme LLC ($45.70) |
| 2019 | $11.36 | 1 | Amgen Inc. ($11.36) |
| 2018 | $203.53 | 10 | Amgen Inc. ($120.61) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/08/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: ONCOLOGY | ||||||
| 04/13/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2022 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: Oncology | ||||||
| 09/09/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $7.78 | General |
| Category: ONCOLOGY | ||||||
| 06/09/2022 | Celgene Corporation | ONUREG (Drug) | Food and Beverage | Cash or cash equivalent | $19.60 | General |
| Category: Oncology | ||||||
| 05/06/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: ONCOLOGY | ||||||
| 04/19/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $8.30 | General |
| Category: ONCOLOGY | ||||||
| 03/23/2022 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $13.93 | General |
| Category: ONCOLOGY | ||||||
| 03/07/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $8.72 | General |
| Category: ONCOLOGY | ||||||
| 01/10/2019 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $11.36 | General |
| 08/09/2018 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $22.85 | General |
| 08/03/2018 | Amgen Inc. | Neulasta (Biological) | Food and Beverage | In-kind items and services | $33.06 | General |
| Category: Oncology | ||||||
| 07/31/2018 | Amgen Inc. | Neulasta (Biological), Vectibix | Food and Beverage | In-kind items and services | $30.33 | General |
| Category: Oncology | ||||||
| 07/26/2018 | Amgen Inc. | Kyprolis (Biological) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: Oncology | ||||||
| 07/26/2018 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $6.45 | General |
| Category: Hematology | ||||||
| 07/20/2018 | PFIZER INC. | SUTENT (Drug), INLYTA, BAVENCIO | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 06/28/2018 | Amgen Inc. | Neulasta (Biological) | Food and Beverage | In-kind items and services | $33.04 | General |
| Category: Oncology | ||||||
| 06/14/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Oncology | ||||||
| 05/15/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $12.68 | General |
| Category: Oncology | ||||||
| 04/12/2018 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $17.53 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 231 | 499 | $93,403 | $44,749 |
| 2022 | 8 | 244 | 595 | $94,294 | $53,551 |
| 2021 | 7 | 249 | 600 | $97,122 | $57,059 |
| 2020 | 8 | 250 | 621 | $94,149 | $54,117 |
Total Patients
974
Total Services
2,315
Medicare Billing
$209,476
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 164 | $25,316 | $15,013 | 59.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 30 | 54 | $14,634 | $6,739 | 46.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 43 | 71 | $11,630 | $5,952 | 51.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 33 | 72 | $13,976 | $5,398 | 38.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 22 | 39 | $12,293 | $4,297 | 35.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 25 | $6,900 | $3,295 | 47.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 43 | $5,164 | $2,451 | 47.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 24 | 31 | $3,490 | $1,605 | 46.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 193 | $28,564 | $15,430 | 54.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 55 | 124 | $18,600 | $12,309 | 66.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 31 | 52 | $12,740 | $7,275 | 57.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 56 | 81 | $10,044 | $5,445 | 54.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 22 | 87 | $9,657 | $4,884 | 50.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 22 | 29 | $8,004 | $4,554 | 56.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $4,725 | $2,652 | 56.1% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 13 | 14 | $1,960 | $1,002 | 51.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 37 | 220 | $32,560 | $17,967 | 55.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 41 | 139 | $20,880 | $13,980 | 67.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 33 | 42 | $11,592 | $6,703 | 57.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 35 | 51 | $10,460 | $6,679 | 63.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 58 | 95 | $11,135 | $6,109 | 54.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 22 | 22 | $6,930 | $3,838 | 55.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 23 | 31 | $3,565 | $1,783 | 50.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 36 | 212 | $31,376 | $18,006 | 57.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 47 | 142 | $19,880 | $11,807 | 59.4% |
About Dr. John Richart, MD
Dr. John Richart, MD is a Hematology & Oncology healthcare provider based in St Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659480242.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Richart, MD has received a total of $350.13 in payments from pharmaceutical and medical device companies, with $36.74 received in 2023. These payments were reported across 20 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($336.20).
As a Medicare-enrolled provider, Richart has provided services to 974 Medicare beneficiaries, totaling 2,315 services with total Medicare billing of $209,476. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location St Louis, MO
- Active Since 08/29/2006
- Last Updated 01/25/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1659480242
Products in Payments
- Neulasta (Biological) $96.43
- KEYTRUDA (Biological) $45.70
- IMBRUVICA (Drug) $36.74
- Imbruvica (Drug) $27.68
- ONUREG (Drug) $19.60
- ERLEADA (Drug) $19.27
- Kyprolis (Biological) $17.73
- SUTENT (Drug) $14.86
- BELEODAQ (Drug) $13.93
- Nplate (Biological) $6.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in St Louis
Roy Morris, Md, MD
Hematology & Oncology — Payments: $1,904
Hematology & Oncology $1,904
Dr. James Glauber, Md, MD
Hematology & Oncology — Payments: $269.98
Hematology & Oncology $269.98
Mr. Gary Ratkin, Md, MD
Hematology & Oncology — Payments: $27.93
Hematology & Oncology $27.93
Dr. Stephen Janney, Md, MD
Hematology & Oncology
Hematology & Oncology
Bader Alahmari, Mbbs, MBBS
Hematology & Oncology
Hematology & Oncology